View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
October 30, 2019updated 12 Jul 2022 12:23pm

Celldex stops Phase Ib/II trial in melanoma due to GI toxicities after enrolling three patients

The study had enrolled three out of its 10-patient target when it was stopped, a source said.

By GlobalData Healthcare

Celldex Therapeutics discontinued the investigator-led Phase Ib trial investigating CDX-3379 in combination with Novartis’ MEK-inhibitor Mekinist (trametinib) in melanoma due to significant gastrointestinal (GI) side effects, a source familiar with the trial said. 

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The study had enrolled three out of its 10-patient target when it was stopped, the source added.

The open-label Phase Ib/II trial (NCT03580382), which is still listed as recruiting on ClinicalTrials.gov, is focused on advanced-stage NRAS-mutant and BRAF/NRAS wild-type melanoma patients.

When asked to comment on this article, a Celldex spokesperson noted that since the trial is an investigator-sponsored initiative, the company is not at liberty to comment. Celldex is sponsoring CDX-3379’s evaluation in a 45-patient, open-label, Phase II head and neck squamous cell carcinoma (HNSCC) trial (NCT03254927) in combination with Eli Lilly’s epidermal growth factor receptor (EGFR) inhibitor Erbitux (cetixumab). The source declined to comment on whether the side effects seen in the melanoma trial might also be an issue in the HNSCC trial.

The melanoma trial page was last updated on 24 January, and the first patient was enrolled on 6 July 2018, according to ClinicalTrials.gov. The Phase Ib portion of the study was meant to determine the dose for Phase II, which would then assess response rates and duration of response.

CDX-3379 is a monoclonal antibody targeting ERBB3, a receptor theorised to have a pivotal role in regulating cancer cell growth and survival, as well as resistance to targeted therapies. Mekinist was approved in May 2013 and is labelled both as a monotherapy and in combination with Novartis’ Tafinlar (dabrafenib) for unresectable or metastatic melanoma with BRAF V600E or V600K mutations. Most common adverse reactions (≥20%) for Mekinist as a single agent include rash, diarrhoea and lymphedema, according to its label.

Celldex has a market cap of $32.74m. The company has had a series of failed therapies, starting in 2016 when its shares went down 54.8% after a preplanned interim analysis revealed that its Phase III ACT IV trial assessing rindopepimut in newly diagnosed EGFRvIII-positive glioblastoma would not reach statistical significance in the primary endpoint of overall survival due to the control arm outperforming. In 2018, Celldex shares dropped 64.9% after its Phase IIb METRIC trial looking into glembatumumab vedotin failed to show benefit versus the comparator in triple-negative breast cancer.

by Reynald Castaneda in London

Reynald Castaneda is a Senior Reporter for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.

  

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena